Dr. Eisner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2650 Ridge Ave
Evanston, IL 60201Phone+1 847-570-2112Fax+1 630-352-5499
Education & Training
- Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
- Loyola University Medical CenterChief Residency, Internal Medicine, 2003 - 2004
- Loyola University Medical CenterResidency, Internal Medicine, 2000 - 2003
- Arizona College of Osteopathic Medicine of Midwestern UniversityClass of 2000
Certifications & Licensure
- IL State License 2000 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
- Join now to see all
Publications & Presentations
PubMed
- 91 citationsPembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Alan Palmer
Blood. 2021-03-11 - 15 citationsSequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma.Pamela B Allen, Xinyan Lu, Qing Chen, Kaitlyn O'Shea, Joan S Chmiel
Blood Advances. 2023-06-27 - 11 citationsCase report and brief review: IL-2-induced myocarditis.Robert M. Eisner, Aliya N. Husain, Joseph I. Clark
Cancer Investigation. 2004-08-18
Professional Memberships
- Member
- Member
- Member
External Links
- Websitehttp://www.nm.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: